Question · asked by 1 review
Pentoxifylline vs Placebo or no active treatment: Difficulty in speech (participant-reported proxy)
- Population
- People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
- Intervention
- Pentoxifylline
- Comparison
- Placebo or no active treatment
- Outcome
- Difficulty in speech (participant-reported proxy)
Pentoxifylline led to lower difficulty in speech (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pentoxifylline vs Placebo or no active treatment Difficulty in speech (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Pentoxifylline led to lower difficulty in speech (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported. Interventions for managing oral submucous fibrosis (2024) · Cochrane All outcomes | OR 0.20 [0.08, 0.48] | 1 study · 106 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes | 2022-09 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.